Trump’s autistic advertisement leaves the parent company for a teleinol with the public relations crisis

Control of damage is ongoing, as the parent company in Tilanol is competing to dispel US President Donald Trump’s claim that the use of Tilanol during pregnancy is linked to an autism spectrum disorder.

Do not take it. A killer like hell so that he does not take itTrump said on Monday, connecting the active ingredient of analgesics, acetaminophen, to the situation.

There is no conclusive evidence that supports the association, and experts warn. Kenvue, which makes Tilanol, said the same.

“We believe an independent flag, a sound flag clearly shows that taking acetaminophen does not cause autism,” a spokesman said in a statement to CBC News. “We are strongly disagreeing with any suggestion otherwise, and we are deeply anxious about the health risks and confusion that this puts to the expectation of mothers and fathers.”

However, Kenvue now must find a way out of the main public relations crisis.

“The burden of proof of the company to re -provide their safety measures,” said Carroll Levin, CEO and co -founder of Energi PR.

Crisis management

Jolly McCarthy, co -founder and head of the Toronto Public Relations Company, said that the repercussions of Tilanol may continue for a long time.

“Monitoring the conversation and trying to face wrong information, while balanced it with accurate information … this is a difficult task,” she said, adding that the company will have probably forced to monitor how this situation is running for a long time, especially on social media.

She said the brand benefits from being a familiar -old name. In addition, the support that Taylinol gets from reliable organizations and experts has a long way.

“In any crisis, especially this crisis, speed occurs significantly,” McCarthy said, adding that the Kenfo statement came quickly and included scientific information, as well as “the language that people can resonate.”

Livin of Engiri, public relations, said that the concern is that medical information is misleading-and that health and pharmaceutical care companies are already fighting to maintain the confidence of the public.

She said, “I don’t see this as one time.” “Today, it’s Tilanol; tomorrow it will be something else. It is vaccines. Then another medicine. Who knows where he will end.”

For this reason, she says, Kenfo and her competitors must work together in public relations campaigns that educate the audience.

“There is an opportunity here for competitors to focus under the same tent,” she said. “Together they represent a stronger voice.”

She said that companies can also cooperate with patient organizations, such as an autism specialist, as they create information campaigns using stories from live experience.

“This will be a great time to activate scientific communications with web seminars and videos and access to the most affected fans.”

“Labor Project”

Trump’s comments may lead to more than just a public relations crisis, as healthcare providers are stuck in the management of repercussions with patients.

Several experts told CBC News that they are already concerned that people who took Tilanol during pregnancy might feel guilty or confused Trump’s comments. They have warned that patients may also inspire the choice of drugs that are not safe. For example, Advil, or IBUPROFEN, is not already recommended after 20 weeks of pregnancy. Because of the possible serious complications.

“It was a truly disappointing comment to hear as a health care presenter,” said Dr. Darren Charry, spokeswoman for the Association of Obstetricians and Gynecology in Canada.

Many organizations around the world – including SOGC, the European Medical Association and the World Health Organization have restored existing medical guidance and repeated that there is no strong scientific evidence to support Trump’s claims. Even the American Food and Drug Administration Admit that “A causal relationship has not been created” between acetaminophen and nerve conditions, although its intention to put safety stickers on Tilanol packaging.

Currently, patients leave the conflicting information management.

Al -Shar says her patients have since asked whether Taylinol was safe, and that the comments have the ability to stigmatize people with autism.

She added that this situation forces health care professionals away from the work that is intended to focus on.

“This is a business project,” Al -Shar said. “Our efforts to find treatments and penetration should be placed instead of correcting wrong information.”